Novartis boosts 2019 targets after third-quarter beat
Share:
ZURICH (Reuters) - Swiss drugmaker Novartis on Tuesday boosted its full-year targets, with sales now expected to grow at a high single-digit percentage rate and core operating income now seen growing at a mid- to high-teen rate. Third-quarter core net income rose 17% at constant currencies to $3.2 billion. Sales were $12.2 billion, compared to the $11.7 billion average in a Refinitiv poll. Zolgensma, the Swiss drugmaker's $2.1 million-per-patient gene therapy for spinal muscular atrophy, posted..